

September 10, 2020



SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim's Antifungal Webinar

JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in a fireside chat at H.C. Wainwright's 22nd Annual Global Investment Healthcare Conference taking place September 14-16, 2020. Dr. Taglietti will also partake in a panel discussion at Maxim's antifungal webinar taking place September 17, 2020.

Presentation details:

H.C. Wainwright 22nd Annual Global Investment Conference

Presentation Tuesday, September 15, 2020

Date:

Presentation 2:30 p.m. ET

Time:

Webcast: <https://wsj.com/webcast/hcw7/register.aspx?conf=hcw7&page=scyx&url=https://wsj.com/webcast/hcw7/scyx>

Maxim's Antifungal Webinar

Webinar Topic: A Too Quiet Pandemic – Fungal Disease

Date: Thursday, September 17, 2020

Time: 11:00 a.m. ET

Register to attend via [link](#)

A webcast of the HCW presentation and a recording of the Maxim webinar will be available for 30 days on the SCYNEXIS website at: <https://www.scynexis.com/news-media/events>

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The [SCYNEXIS team](#) has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida* and *Aspergillus* species. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations

Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com



Source: Scynexis